Biotech Goes Sky-High After LSD Drug Treats Depression
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Biotech Goes Sky-High After LSD Drug Treats Depression" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Fierce Biotech, Business Wire and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 145d ago.
Quick answers
Why is "Biotech Goes Sky-High After LSD Drug Treats Depression" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 147d ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 147d ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 147d ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 147d ago
- Biotech Goes Sky-High After LSD Drug Treats Depression Investor's Business Daily · 147d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson has agreed to buy Austin-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease treatments.
Trump Backs Jensen Huang After Nvidia CEO Confirmed His Affair
President Donald Trump suggested Tim Cook should replace Jensen Huang as Nvidia CEO following Huang's resignation.
Nebrasketball Goes to Uncasville, Leaves with Win Over Providence
Nebraska basketball defeats Providence 67-58 in a neutral-site matchup at Mohegan Sun in Uncasville, securing an early-season resume win.
Berkshire After Buffett: Steady Hands, Big Bets In The Greg Abel Era
Market analysts focus on Greg Abel's upcoming 13F filing and portfolio strategy at Berkshire Hathaway.
After the US midterm rout of Trumpism, the world struggles to trust America again
Democrats won control of both houses of Congress in a midterm rout of Trumpism, but global leaders and citizens say one election does not restore trust in America.